Application of ctDNA in the Evaluation of Curative Effect and Prognosis of SCLC Patients
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorXiangya Hospital of Central South University
About this trial
The purpose of this study is to evaluate the application value of circulating tumor DNA(ctDNA) with efficacy evaluation and prognostic assessment in patients with unresectable SCLC, who were receiving radiotherapy and chemotherapy treatment.
Eligibility criteria
Qualifiers
Provision of informed consent；
Newly diagnosed and histological or cytological confirmed extensive stage small cell lung cancer;
All indicators has confirmed and allow to receive radiotherapy and chemotherapy;
Follow-up can be carried out and the peripheral blood samples can be collected;
Disqualifiers
Patients have other primary cancers;
Patients unable to cooperate with the study for follow-up according to the determined clinical follow-up cycle;
Unable to accept the judgment of curative effect evaluation by the designated methods such as CT.
Trial design
Treatments tested in this trial
- Observation
Treatment groups
No treatment groups listed
Locations
Sponsors and collaborators
Source ClinicalTrials.gov